Numab Therapeutics

Numab Therapeutics is a biopharmaceutical company focused on oncology, dedicated to the invention of antibody-based therapies. The molecules designed by the company possess tailored pharmacological properties, such as multispecific products with short or long half-lives. Numab AG has created a series of patented antibody-based projects and provides innovative antibody-based therapies on behalf of partners in the pharmaceutical industry. The company designs and develops new therapies for serious diseases. Its plug-and-play platform significantly reduces the randomness of the discovery process, predictably generating multispecific biologics ready for development against chronic inflammation and cancer. With our proprietary MATCH™ technology platform, we are driving a new wave of multispecific drug candidates, designing them with versatility and developability. Our lead product aims to balance potent anti-tumor immunity with desirable safety by simultaneously targeting 4-1BB, PD-L1, and human serum albumin. We believe that adhering to the highest quality standards at every step of the drug design process will lead to better outcomes for patients.